Ocrelizumab
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Ocrelizumab. Ocrelizumab is a second generation humanised anti CD20 antibody. It depletes B cells. Fully referenced neurology checklist.
Mode of action
- Ocrelizumab is a second generation humanised anti CD20 antibody
- It depletes B cells
Indications
Locked: subscribe to see this section.
Benefits in primary progressive MS
Locked: subscribe to see this section.
Intravenous administration
Locked: subscribe to see this section.
Subcutaneous administration
Locked: subscribe to see this section.
Neurological side effects
Locked: subscribe to see this section.
Infectious side effects
Locked: subscribe to see this section.
Systemic side effects
Locked: subscribe to see this section.
Obstetric aspects
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
Withdrawal
Locked: subscribe to see this section.
References
- Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 2016; 9:44-52.
- Montalban X, Hauser SL, Kappos L, et al; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376:209-220.
- Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779-1787.
- Hauser SL, Bar-Or A, Comi G, et al; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376:221-234.
- Barkhof F, Kappos L, Wolinsky JS, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology 2019; doi: 10.1212/WNL.0000000000008189 (Epub ahead of print).
- And 27 more. Subscribe to see the full list
